Quadrupled Flu Shot Serves Seniors Better, Researchers Say
A recent study by the Rochester School of Medicine found that investigational high-dose influenza vaccine demonstrated increased immune responses among adults 65 years of age and older compared with the standard flu vaccine. As a result of this report, vaccine maker Sanofi Aventis is formulating a high-dose IM influenza vaccine. The CDC explains that older adults become not only more susceptible to infections, but also less responsive to vaccinations. The development of an influenza vaccine that will provide improved immune response in older adults is important because this population has the highest rates of complications from influenza, according to the researchers.